Day: November 19, 2019

MONACO, Nov. 19, 2019 (GLOBE NEWSWIRE) — Scorpio Tankers Inc. (NYSE:STNG) (“Scorpio Tankers,” or the “Company”) announced that the President of the Company, Robert Bugbee, has purchased call options on 200,000 common shares (or 2,000 call option contracts) of the Company with strike price of $32.00 and an expiration of January 2020 for the consideration of $450,000.About Scorpio Tankers Inc.Scorpio Tankers is a provider of marine transportation of petroleum products worldwide. The Company currently owns or finance leases 124 product tankers (42 LR2 tankers, 12 LR1 tankers, 56 MR tankers and 14 Handymax tankers) with an average age of 3.9 years and bareboat charters-in 10 product tankers (three MR tankers and seven Handymax tankers). In addition, the Company will bareboat charter-in four MR tankers that are currently under construction...

TORONTO, Nov. 19, 2019 (GLOBE NEWSWIRE) — Pure Global Cannabis Inc. (TSX.V:PURE; OTC: PRCNF) (the “Company” or “Pure Global” or “Pure”), an integrated growth-oriented cannabis bulk extracts and consumer products manufacturing company, operating through its wholly-owned subsidiary PureSinse Inc., a Health Canada Licensed Producer under the Cannabis Act, is very pleased to announce that it has received approvals from Health Canada to amend its existing license to add manufacturing capabilities via phase 2 of its already licensed facility in Brampton. Having completed their facility in the spring, the Company can begin cultivation and extraction immediately now that all approvals have been granted. This is a transformational event for the Company as it enables its own production as opposed to previously being dependent on wholesale purchases...

SAN DIEGO, Nov. 19, 2019 (GLOBE NEWSWIRE) — Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented Pfēnex Expression Technology platform, the Company has developed the FDA-approved PF708 product indicated for the treatment of osteoporosis in certain patients at high risk of fracture and created an advanced pipeline of therapeutic equivalents, biologics and vaccines. The Company announced today that Eef Schimmelpennink, President and Chief Executive Officer, will be presenting at the Evercore ISI HealthCONx Conference 2019 on Tuesday, December 3rd, taking place at the Four Seasons Hotel in Boston, Massachusetts.Interested parties can access the live audio webcast...

BOSTON and CARSLBAD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the closing of the exclusive licensing agreement with Pfizer Inc. (NYSE:PFE) for AKCEA-ANGPTL3-LRx  following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act). AKCEA-ANGPTL3-LRx is an investigational antisense therapy discovered by Ionis and being developed to treat patients with certain cardiovascular and metabolic diseases. As previously announced, under terms of the agreement Akcea and Ionis will receive a $250 million upfront license fee, which will be split equally between the two companies. Akcea will settle its $125 million obligation to Ionis...

BELTSVILLE, Md., Nov. 19, 2019 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the closing of its public offering of 4,077,192 shares of its common stock at a public offering price of $36.75 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $150 million. NextCure’s common stock is listed on The Nasdaq Global Select Market under the ticker symbol “NXTC.”Morgan Stanley, BofA Securities and Piper Jaffray & Co. acted as joint book-running managers for the offering. Needham & Company and BTIG acted as co-managers for the offering.A...

JERSEY CITY, N.J., Nov. 19, 2019 (GLOBE NEWSWIRE) — Verisk (Nasdaq:VRSK), a leading data analytics provider, announces the addition of Laura K. Ipsen to its board of directors, effective January 1. Ipsen has more than 25 years of experience as a technology executive. She’s currently president and chief executive officer of Ellucian, which provides software and services that power more than 2,500 higher education institutions in more than 50 countries.“Verisk serves a spectrum of industries in data- and technology-rich environments, and Laura’s decades of experience in these arenas will further strengthen the composition of our board,” said Verisk Chairman, President, and CEO Scott G. Stephenson. “Her knowledge of the cloud, AI, and global energy efforts will challenge our assumptions and push us to continue finding new ways to solve...

PHILADELPHIA, Nov. 19, 2019 (GLOBE NEWSWIRE) — Urban Outfitters, Inc. (NASDAQ:URBN), a leading lifestyle products and services company which operates a portfolio of global consumer brands comprised of Anthropologie, BHLDN, Free People, Terrain, Urban Outfitters and Nuuly brands and the Food and Beverage division, today announced net income of $56 million and $149 million for the three and nine months ended October 31, 2019, respectively. Earnings per diluted share were $0.56 and $1.47 for the three and nine months ended October 31, 2019, respectively.Total Company net sales for the three months ended October 31, 2019, increased 1.4% over the same period last year to $987 million. Comparable Retail segment net sales increased 3%, driven by growth in the digital channel, partially offset by negative retail store sales. By brand, comparable...

CHARLOTTESVILLE, Va., Nov. 19, 2019 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, announces increased survival in inoperable glioblastoma patients enrolled in the 19-patient, open-label, dose-escalation lead-in portion of its Phase 3 study with Trans Sodium Crocetinate (TSC) plus standard of care (SOC).  John Gainer, Ph.D., the Company’s chief scientific officer, will present details of these findings at the inaugural Glioblastoma Drug Development Summit being held in Boston December 10-11, and sponsored by Hanson Wade. Dr. Gainer’s slide presentation will be posted to the Company’s website at www.diffusionpharma.com immediately...

FREMONT, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) — Lam Research Corporation (Nasdaq: LRCX) today announced its participation at an upcoming investor event:Tuesday, December 3,  2019  –  Credit Suisse 23rd Annual Technology Conference 11:05 a.m. Mountain Time.A live webcast of the presentation will be available to the public and can be accessed from the Investors’ section of Lam’s website at www.lamresearch.com.  A replay of the webcast will be available for two weeks after the presentation date.About Lam Research:Lam Research Corporation is a global supplier of innovative wafer fabrication equipment and services to the semiconductor industry. As a trusted, collaborative partner to the world’s leading semiconductor companies, we combine superior systems engineering capability, technology leadership, and unwavering commitment to customer...

SAN JOSE, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) — NETGEAR, Inc. (NASDAQ: NTGR), the industry’s leading provider of leading-edge networking products for the home and office, today announced that John McHugh, its Senior Vice President, SMB Products and Services, plans to retire from the Company at the end of 2019.  NETGEAR also named Vikram Mehta as Mr. McHugh’s successor, and plans to appoint Mr. Mehta Senior Vice President, SMB Products and Services effective as of January 2, 2020.Mr. McHugh has been the leader of the Company’s SMB business over the last seven years, and will remain in his current role with the Company to ensure a smooth transition to Mr. Mehta.  Mr. Mehta previously served as CEO and President of Blade Network Technologies, which was acquired by IBM.  Prior to Blade, Mr. Mehta held senior roles at Nortel Networks,...